Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.
about
Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia.EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-γ1) as a potential target for t(8;21) AML.MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia.EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.Systems medicine approaches for peptide array-based protein kinase profiling: progress and prospects.Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia.Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: a new approach for target discovery.Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
P2860
Q30243925-E7834F46-8FEE-4E8A-9F95-189140F2EE98Q36053792-BBC9DDA0-BDEF-4E47-9685-E3037BF739DDQ37633585-96850857-AD13-41B5-9553-445DF0D94F35Q38745849-EB2639A2-6DF1-47A1-BD90-14B012B4629FQ38871097-2B2D89C4-315E-4A7A-A434-A235D2606A0DQ38878649-E4CBAD3C-7264-42D8-B363-BAACD4EF2598Q38969204-A26F1949-CDE2-4799-9AEF-3B3C1889E899Q38974705-5385D8A1-A980-4076-B291-6C56DB3E516FQ41815540-EA3B9290-745F-48CA-9A93-0AB7AC32228FQ42314704-97B76207-65BA-4675-B5A6-5BE8DB4D1D65Q42380390-14491327-D3D0-4EA7-B1DA-4E88892FE935Q42383776-E25FEC86-A283-4831-8760-F6BC52620AD1Q47600932-DEDBB652-1A5E-4368-9A6B-730F5F3C6208Q48151269-7FC263BB-DF6D-405C-8995-287386982FDAQ51729425-87897797-0F1A-4EA5-ADFC-13764A0A8D22Q52608455-8557FC52-90BE-4CB1-8762-C8174128D954Q54308039-1E1E6BA7-E433-4015-97A7-6B0E4316E51DQ54315033-083089D5-E992-4A7C-9126-77F8E3D7C2AD
P2860
Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Insights in dynamic kinome rep ...... ibition in MLL-rearranged AML.
@en
Insights in dynamic kinome rep ...... ibition in MLL-rearranged AML.
@nl
type
label
Insights in dynamic kinome rep ...... ibition in MLL-rearranged AML.
@en
Insights in dynamic kinome rep ...... ibition in MLL-rearranged AML.
@nl
prefLabel
Insights in dynamic kinome rep ...... ibition in MLL-rearranged AML.
@en
Insights in dynamic kinome rep ...... ibition in MLL-rearranged AML.
@nl
P2093
P2860
P50
P356
P1433
P1476
Insights in dynamic kinome rep ...... hibition in MLL-rearranged AML
@en
P2093
A Ter Elst
E S J M de Bont
F J G Scherpen
P2860
P2888
P304
P356
10.1038/LEU.2013.342
P577
2013-11-18T00:00:00Z